Medical Therapy of Fibrostenotic Crohn's Disease

Overview

Journal Viszeralmedizin

Publisher Karger

Date 2015 Nov 12

PMID 26557834

Citations 1

Authors

Britta Siegmund

Affiliations

Soon will be listed here.

Abstract

Introduction: The present review serves to provide a concise overview of the current knowledge on therapeutic strategies with regard to fibrostenotic lesions in Crohn's disease.

Methods: A literature search was performed focusing on the last 5 years, and current concepts of pathophysiology, epidemiology, and treatment have been summarized.

Results: Fibrostenotic lesions in Crohn's disease are currently considered to be a consequence of the chronic inflammatory nature of the disease. Hence, therapeutic strategies are limited to the concept that early treatment of the inflammatory lesions can prevent structural changes, and to various endoscopic and surgical approaches. Direct targeting of the fibrostenotic lesion itself has not been the focus until now. This review will provide an overview of the pathophysiology and epidemiology of fibrostenotic lesions including current therapeutic approaches. Since research with regard to other organ systems and fibrosis is far more advanced, current strategies from available studies in these areas will be discussed. The results and the potential impact for Crohn's disease will be considered.

Conclusion: The vision of these approaches is to reverse structural changes and restore normal function.

Citing Articles

Tumor necrosis factor receptor-associated factor 5 enhances perianal fistulizing Crohn's disease through epithelial-mesenchymal transition.

Sun X, Gao H, Lu L, Wang Q, Li Y, Gu Y Cytojournal. 2025; 21:82.

PMID: 39917000 PMC: 11801662. DOI: 10.25259/Cytojournal_148_2024.

Shear Wave and Strain Elastography in Crohn's Disease-A Systematic Review.

Grazynska A, Kufel J, Dudek A, Cebula M Diagnostics (Basel). 2021; 11(9).

PMID: 34573952 PMC: 8468946. DOI: 10.3390/diagnostics11091609.

References

Zvidi I, Hazazi R, Birkenfeld S, Niv Y . The prevalence of Crohn's disease in Israel: a 20-year survey. Dig Dis Sci. 2008; 54(4):848-52. DOI: 10.1007/s10620-008-0429-1. View

Friedman S, Sheppard D, Duffield J, Violette S . Therapy for fibrotic diseases: nearing the starting line. Sci Transl Med. 2013; 5(167):167sr1. DOI: 10.1126/scitranslmed.3004700. View

Raghu G, Brown K, Costabel U, Cottin V, du Bois R, Lasky J . Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med. 2008; 178(9):948-55. DOI: 10.1164/rccm.200709-1446OC. View

Rousseaux C, Desreumaux P . [The peroxisome-proliferator-activated gamma receptor and chronic inflammatory bowel disease (PPARgamma and IBD)]. J Soc Biol. 2006; 200(2):121-31. DOI: 10.1051/jbio:2006015. View

Hawinkels L, Ten Dijke P . Exploring anti-TGF-β therapies in cancer and fibrosis. Growth Factors. 2011; 29(4):140-52. DOI: 10.3109/08977194.2011.595411. View

Ambe R, Campbell L, Cagir B . A comprehensive review of strictureplasty techniques in Crohn's disease: types, indications, comparisons, and safety. J Gastrointest Surg. 2011; 16(1):209-17. DOI: 10.1007/s11605-011-1651-2. View

Osman B, Akool E, Doller A, Muller R, Pfeilschifter J, Eberhardt W . Differential modulation of the cytokine-induced MMP-9/TIMP-1 protease-antiprotease system by the mTOR inhibitor rapamycin. Biochem Pharmacol. 2010; 81(1):134-43. DOI: 10.1016/j.bcp.2010.09.011. View

Wang S, Wilkes M, Leof E, Hirschberg R . Noncanonical TGF-beta pathways, mTORC1 and Abl, in renal interstitial fibrogenesis. Am J Physiol Renal Physiol. 2009; 298(1):F142-9. PMC: 2806113. DOI: 10.1152/ajprenal.00320.2009. View

Wibmer A, Kroesen A, Grone J, Buhr H, Ritz J . Comparison of strictureplasty and endoscopic balloon dilatation for stricturing Crohn's disease--review of the literature. Int J Colorectal Dis. 2010; 25(10):1149-57. DOI: 10.1007/s00384-010-1010-x. View

10.

Jacobsen B, Fallingborg J, Rasmussen H, Nielsen K, Drewes A, Puho E . Increase in incidence and prevalence of inflammatory bowel disease in northern Denmark: a population-based study, 1978-2002. Eur J Gastroenterol Hepatol. 2006; 18(6):601-6. DOI: 10.1097/00042737-200606000-00005. View

11.

Meng F, Wang K, Aoyama T, Grivennikov S, Paik Y, Scholten D . Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology. 2012; 143(3):765-776.e3. PMC: 3635475. DOI: 10.1053/j.gastro.2012.05.049. View

12.

Hueber W, Sands B, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins P . Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012; 61(12):1693-700. PMC: 4902107. DOI: 10.1136/gutjnl-2011-301668. View

13.

Theiss A, Simmons J, Jobin C, Lund P . Tumor necrosis factor (TNF) alpha increases collagen accumulation and proliferation in intestinal myofibroblasts via TNF receptor 2. J Biol Chem. 2005; 280(43):36099-109. DOI: 10.1074/jbc.M505291200. View

14.

Dheda K, Lalloo U, Cassim B, Mody G . Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clin Rheumatol. 2004; 23(4):306-9. DOI: 10.1007/s10067-004-0906-7. View

15.

Latella G, Sferra R, Speca S, Vetuschi A, Gaudio E . Can we prevent, reduce or reverse intestinal fibrosis in IBD?. Eur Rev Med Pharmacol Sci. 2013; 17(10):1283-304. View

16.

Azuma A . Pirfenidone treatment of idiopathic pulmonary fibrosis. Ther Adv Respir Dis. 2012; 6(2):107-14. DOI: 10.1177/1753465812436663. View

17.

Kumagai S, Ohtani H, Nagai T, Funa K, Hiwatashi N, Shimosegawa . Platelet-derived growth factor and its receptors are expressed in areas of both active inflammation and active fibrosis in inflammatory bowel disease. Tohoku J Exp Med. 2002; 195(1):21-33. DOI: 10.1620/tjem.195.21. View

18.

Bargagli E, Galeazzi M, Bellisai F, Volterrani L, Rottoli P . Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension. Respiration. 2005; 75(3):346-9. DOI: 10.1159/000090248. View

19.

Reinisch W, Panes J, Lemann M, Schreiber S, Feagan B, Schmidt S . A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease. Am J Gastroenterol. 2008; 103(9):2284-92. DOI: 10.1111/j.1572-0241.2008.02024.x. View

20.

Scaldaferri F, Vetrano S, Sans M, Arena V, Straface G, Stigliano E . VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology. 2008; 136(2):585-95.e5. DOI: 10.1053/j.gastro.2008.09.064. View